
- /
- Supported exchanges
- / US
- / LUCD.NASDAQ
Lucid Diagnostics Inc (LUCD NASDAQ) stock market data APIs
Lucid Diagnostics Inc Financial Data Overview
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Lucid Diagnostics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Lucid Diagnostics Inc data using free add-ons & libraries
Get Lucid Diagnostics Inc Fundamental Data
Lucid Diagnostics Inc Fundamental data includes:
- Net Revenue: 4 360 K
- EBITDA: -47 060 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lucid Diagnostics Inc News

Lucid Diagnostics dips after pricing $25M stock offering
* Lucid Diagnostics (NASDAQ:LUCD [https://seekingalpha.com/symbol/LUCD]) fell over 17% premarket on Wednesday after it priced a public offering of 25 million shares at $1.00 each. * Underwriters a...


Lucid Diagnostics announces proposed public offering of common stock
* Lucid Diagnostics (NASDAQ:LUCD [https://seekingalpha.com/symbol/LUCD]) announced on Tuesday its intention to offer shares [https://seekingalpha.com/pr/20226999-lucid-diagnostics-announces-proposed...

Karman Holdings Reaches Analyst Target Price
In recent trading, shares of Karman Holdings Inc (Symbol: KRMN) have crossed above the average analyst 12-month target price of $53.25, changing hands for $54.73/share. When a stock reaches the targe...

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasia Lucid Diagnostics to collaborate with PAVmed as ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.